- Reported transaction lines
- 3
- Buy lines
- 0
- Sell lines
- 0
Filing activity by month
Original filing lines in up to 12 months with activity.
- 2026-113
Frequently disclosed stocks
Disclosure history
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source |
|---|---|---|---|---|---|---|
| MUIR GLENN P Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 47840 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2026; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting on May 18, 2027 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2027 and each August 18 thereafter. | 2026-11-18 | 2026-11-20 | 4,629 shares/units | SEC 4 |
| MUIR GLENN P Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 7715 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. | 2026-11-18 | 2026-11-20 | 4,629 shares/units | SEC 4 |
| MUIR GLENN P Director · Neuronetics, Inc. | STIM Neuronetics, Inc. | Equity grant or awardFiling detailsSEC transaction code A Original filed 2026-11-18 Common Stock · Direct ownership · Reported balance after transaction: 576816 · The Form 4 filed on November 18, 2026 inadvertently refereed to shares sold in the footnote describing the average weighted price. This Form 4 is therefore being filed to correct the footnote to refer to a purchase. · The price reported is a weighted average price. These shares were purchased in multiple transactions at per share prices ranging from $1.25 to $1.385. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. | 2026-11-16 | 2026-11-19 | 175,000 shares/units | SEC 4/A Amendment |
| MUIR GLENN P Director · Neuronetics, Inc. | STIM Neuronetics, Inc. | Equity grant or awardFiling detailsSEC transaction code A Common Stock · Direct ownership · Reported balance after transaction: 576816 · The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $1.25 to $1.385. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | 2026-11-16 | 2026-11-18 | 175,000 shares/units | SEC 4 |
Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.